Earnings Call Summary | Helius Medical Technologies(HSDT.US) Q4 2023 Earnings Conference
Earnings Call Summary | Helius Medical Technologies(HSDT.US) Q4 2023 Earnings Conference
The following is a summary of the Helius Medical Technologies, Inc. (HSDT) Q4 2023 Earnings Call Transcript:
以下是Helius Medical Technologies, Inc. (HSDT) 2023年第四季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
Helius Medical Technologies reported a Q4 2023 revenue of $134,000, a decrease from Q4 2022's $282,000.
Cost of revenue for Q4 2023 was lower at $90,000, compared to Q4 2022's $150,000.
Operating loss was narrowed to $2.2 million in Q4 2023, from a loss of $2.7 million in Q4 2022.
Net loss was significantly decreased to $1 million in Q4 2023, down from $4.9 million in Q4 2022.
As of the end of 2023, the company had $5.2 million in cash with no debt.
Helius Medical Technologies报告称，2023年第四季度收入为13.4万美元，低于2022年第四季度的28.2万美元。
2023年第四季度的收入成本低于9万美元，而2022年第四季度的收入成本为15万美元。
营业亏损从2022年第四季度的270万美元亏损缩小至2023年第四季度的220万美元。
净亏损从2022年第四季度的490万美元大幅下降至2023年第四季度的100万美元。
截至2023年底，该公司拥有520万澳元的现金，没有债务。
Business Progress:
业务进展：
Helius made progress in 2023 towards securing widespread reimbursement for their PoNS device and FDA approval for stroke treatment.
Unique HCPCS codes were obtained for the PoNS controller and mouthpiece.
A program started, aiming to validate the effectiveness of PoNS Therapy for stroke patients.
Regulatory submission for the therapy is planned for early 2025.
Canadian expansion continues and 2024 is expected to bring steady progress towards overall company goals.
The company implemented a telemedicine and e-prescribing hub aiming for speedy delivery of their PoNS devices.
Partnerships were made with UpScript and neurologists for quicker online diagnoses and e-prescriptions.
Online PoNS module training for physical therapists has also been established.
Six Centers of Excellence were added for the PoNS step clinical trial in 2023.
Veteran Affairs rehab specialists have shown interest in the PoNS device due to prevalence of balance issues in veterans.
Finally, the company will work towards procuring coverage and reimbursement for PoNS therapy.
2023年，Helius在确保其PoNs设备的广泛报销和美国食品药品管理局批准中风治疗方面取得了进展。
获得了 PonS 控制器和喉舌的独特的 HCPCS 代码。
启动了一项计划，旨在验证PonS疗法对中风患者的有效性。
该疗法的监管申请计划于2025年初提交。
加拿大的扩张仍在继续，预计2024年将在实现公司总体目标方面取得稳步进展。
该公司实施了远程医疗和电子处方中心，旨在快速交付其PoNs设备。
与UpScript和神经科医生建立了合作伙伴关系，以更快地进行在线诊断和电子处方。
还为物理治疗师建立了在线PonS模块培训。
2023 年，PonS step 临床试验增加了六个卓越中心。
由于退伍军人普遍存在平衡问题，退伍军人事务康复专家对PonS设备表现出兴趣。
最后，该公司将努力为PonS疗法争取保险和报销。
More details: Helius Medical Technologies IR
更多详情： Helius 医疗科技 IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由 AI 生成。无法完全保证内容的准确性。欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。